Skip to main content

Table 1 Clinicopathological characteristics of OSC patients from TCGA

From: A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma

Characteristics

Groups

Patients

  

Total (N = 551)

Training dataset (N = 368)

Validation dataset (N = 183)

No.

%

No.

%

No.

%

Age at diagnosis

Median

59

 

60

 

59

 

Range

26–89

 

34–87

 

30–89

 

< 60

286

50.44

187

50.95

104

63.41

≥ 60

265

46.74

182

49.59

79

48.17

FIGO stage

I

15

2.65

5

1.36

10

6.10

II

27

4.76

12

3.27

15

9.15

III

423

74.60

287

78.20

136

82.93

IV

82

14.46

62

16.89

20

12.20

Unknown

4

0.71

2

0.54

2

1.22

Histologic grade*

G2

69

12.17

25

6.81

44

26.83

G3

478

84.30

341

92.92

137

83.54

G4

1

0.18

1

0.27

0

0.00

Others

3

0.53

1

0.27

2

1.22

Tumor residual (mm)

No macroscopic disease

116

20.46

67

18.26

49

29.88

1–10

244

43.03

191

52.04

53

32.32

11–20

33

5.82

16

4.36

17

10.37

> 20

105

18.52

64

17.44

41

25.00

Unknown

53

9.35

33

8.99

25

15.24

Anatomic subdivision

Bilateral

383

67.55

253

68.94

130

79.27

Left

78

13.76

55

14.99

23

14.02

Right

62

10.93

40

10.90

22

13.41

Unknown

28

4.94

20

5.45

8

4.88

  1. *G1 and GB/GX were excluded in this study as these tumors may have a different biological behavior